Frequent varicella zoster reactivation associated with therapeutic use of arsenic trioxide: Portents of an old scourge - 21/08/11
Doi : 10.1016/j.jaad.2005.07.030
Wing-Yan Au, MRCP, Yok-Lam Kwong, MD ⁎ 
From the University Department of Medicine, Queen Mary Hospital
Reprint requests: Y. L. Kwong, MD, Department of Medicine, University of Hong Kong, Professorial Block, Queen Mary Hospital, Pokfulam Road, Hong Kong.Hong Kong
Abstract |
In 44 patients treated with arsenic trioxide (As2O3) for acute promyelocytic leukemia, 11 developed varicella zoster virus (VZV) reactivation (median 56 days [range 15-299]) after treatment. There was no preferential dermatome involvement or systemic spread. The actuarial risk of VZV reactivation at 1 year was 26%. No VZV reactivation occurred after the first year of initial treatment with As2O3.
Le texte complet de cet article est disponible en PDF.Plan
| Funding sources: The S. K. Yee Medical Foundation funded the production of oral arsenic trioxide and is thanked by the authors for its support. Conflicts of interest: None identified. |
© 2005
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 53 - N° 5
P. 890-892 - novembre 2005 Retour au numéro
Article précédent
- Etanercept improves the health-related quality of life of patients with psoriasis: Results of a phase III randomized clinical trial
- Steven R. Feldman, Alexa Boer Kimball, Gerald G. Krueger, J. Michael Woolley, Deepa Lalla, Angelika Jahreis
- Bound volumes available to subscribers
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?